This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
AzurRx (AZRX) Pancreatic Insufficiency Study Meets Endpoints
by Zacks Equity Research
AzurRx (AZRX) is developing lead pipeline candidate as monotherapy and in combination regimen as potential treatment for exocrine pancreatic insufficiency in patients with cystic fibrosis.
HZNPPositive Net Change RGENNegative Net Change AZRXPositive Net Change
biotechs
Sutro (STRO) Ovarian Cancer Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
Sutro's (STRO) investigational antibody-drug conjugate therapy, STRO-002, gets Fast Track designation from the FDA for advanced ovarian cancer.
BMYNegative Net Change MRNAPositive Net Change IMGNPositive Net Change STRONegative Net Change
biotechs immuno-therapy medical
US Set to Receive COVID-19 Vaccine Booster Dose Next Month
by Indrajit Bandyopadhyay
In order to provide better protection to the American people from rising COVID-19 cases due to the surge of the Delta variant, U.S. health officials are recommending use of a booster dose for individuals starting this fall.
JNJPositive Net Change PFENegative Net Change MRNAPositive Net Change BNTXNegative Net Change
biotechs messenger-rna pharmaceuticals
Eyenovia (EYEN) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Eyenovia (EYEN) has been struggling lately, but the selling pressure may be coming to an end soon.
biotechnology biotechs
Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and CureVac (CVAC) among others were in focus in the biotech industry over the past week.
GSKNegative Net Change MRNAPositive Net Change EXELPositive Net Change RIGLNegative Net Change CVACNegative Net Change
biotechs pharmaceuticals
Gritstone (GRTS) Inks Deal With CEPI for Coronavirus Vaccine
by Zacks Equity Research
Gritstone (GRTS) signs an agreement with CEPI for up to $20.6 million to develop its COVID-19 vaccine program with an initial focus in South Africa. Shares rise.
AZNNegative Net Change MRNAPositive Net Change GRTSNo Net Change BNTXNegative Net Change
biotechs
Delta Variant Catches Up with the Stock Market
by Mark Vickery
Today, worries about growth and demand, at least partially caused by the Delta variant of Covid-19 manifesting in pockets of America.
AMZNNegative Net Change BIIBPositive Net Change PFENegative Net Change GILDPositive Net Change VRTXNegative Net Change
biotechs consumer-discretionary consumer-staples medical
Travere (TVTX) Announces Data on Rare Kidney Disease Drug
by Zacks Equity Research
Travere (TVTX) announces positive interim data from the ongoing study of its investigational candidate, sparsentan, for the treatment of IgAN, a rare kidney disorder. Resultantly, the stock rises
VRTXNegative Net Change HZNPPositive Net Change RGENNegative Net Change TVTXNegative Net Change
biotechs medical
Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why
by Zacks Equity Research
Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.
BEAMNegative Net Change EDITNegative Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs crispr gene-editing
Sesen's (SESN) Bladder Cancer Drug Vicineum Gets CRL From FDA
by Zacks Equity Research
Sesen's (SESN) biologics license application filed for Vicineum to treat BCG-unresponsive non-muscle invasive bladder cancer fails to secure approval. The stock declines resultantly.
AZNNegative Net Change VRTXNegative Net Change MRNAPositive Net Change SESNPositive Net Change
biotechs medical
Moderna (MRNA) Gets EUA for Third Dose of COVID-19 Vaccine
by Zacks Equity Research
The FDA authorizes third dose of Moderna's (MRNA) COVID-19 vaccine for use in immunocompromised adults.
JNJPositive Net Change PFENegative Net Change MRNAPositive Net Change BNTXNegative Net Change
biotechs messenger-rna
Rigel (RIGL) COVID-19 Treatment Denied By FDA for EUA
by Zacks Equity Research
Rigel Pharmaceuticals' (RIGL) fostamatinib does not get the FDA's nod for emergency use for COVID-19. The company plans to submit data from a larger study.
REGNPositive Net Change GSKNegative Net Change LLYNegative Net Change RIGLNegative Net Change
biotechs
Implied Volatility Surging for Iovance (IOVA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Iovance (IOVA) stock based on the movements in the options market lately.
IOVAPositive Net Change
biotechs medical
Moderna ETFs to Shine Bright on Booster Update, New Study Data
by Sweta Jaiswal, FRM
Moderna is expected to gain on approval for booster shots and new positive data on its COVID-19 vaccine.
PFENegative Net Change MRNAPositive Net Change IBBNegative Net Change BBHPositive Net Change IDNANegative Net Change
biotechs etfs
Here is Why Prothena (PRTA) is Up More Than 155% in Three Months
by Zacks Equity Research
Prothena (PRTA) surges substantially in the past three months on solid prospects of its AD candidates following Biogen???s AD drug approval.
BIIBPositive Net Change BMYNegative Net Change NVONegative Net Change PRTANegative Net Change
biotechs pharmaceuticals
How Are Biotech ETFs Reacting to These Q2 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
BIIBPositive Net Change AMGNNegative Net Change GILDPositive Net Change IBBNegative Net Change XBINegative Net Change BBHPositive Net Change
biotechs etfs
FibroGen's (FGEN) Drug for Anemia of CKD Gets CRL From FDA
by Zacks Equity Research
NDA for roxadustat, FibroGen's (FGEN) candidate for anemia of chronic kidney disease, fails to secure approval as the FDA requests additional clinical data on the drug. The stock declines resultantly.
AZNNegative Net Change IRWDNegative Net Change RGENNegative Net Change FGENNegative Net Change
biotechs
Biotech Stock Roundup: REGN Q2 Earnings Beat, BLUE, BYSI's Updates & More
by Zacks Equity Research
The biotech sector was in focus last week on earnings results from Regeneron (REGN) and regulatory update from bluebird (BLUE) among others.
REGNPositive Net Change SNYPositive Net Change GILDPositive Net Change SGENPositive Net Change BYSINegative Net Change
biotechs medical pharmaceuticals
mRNA COVID-19 Vaccine Makers Lose Steam After Strong Rally
by Indrajit Bandyopadhyay
Stocks of mRNA-based COVID-19 vaccine makers, MRNA, PFE and BNTX fall for two consecutive days on bearish sentiments after a strong rally as well as probable side-effects of their vaccines.
PFENegative Net Change MRKPositive Net Change AMGNNegative Net Change MRNAPositive Net Change BNTXNegative Net Change
biotechs messenger-rna pharmaceuticals
Jazz's (JAZZ) Epidyolex Gets Approval for New Indication in UK
by Zacks Equity Research
Jazz's (JAZZ) unit GW Pharmaceuticals' Epidyolex (cannabidiol) gets a regulatory nod for a new indication in the United Kingdom. Following this announcement, stock prices fell.
IRWDNegative Net Change JAZZNegative Net Change HZNPPositive Net Change CTLTPositive Net Change
biotechs marijuana medical
Perrigo (PRGO) Q2 Earnings Lag, Sales Hurt by Weak Cold Season
by Zacks Equity Research
Perrigo (PRGO) reports dismal second-quarter 2021 results. Stock down.
VRTXNegative Net Change MRNAPositive Net Change PRGOPositive Net Change HZNPPositive Net Change
biotechs earnings
Epizyme's (EPZM) Q2 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Epizyme (EPZM) reports wider-than-expected loss for the second quarter of 2021 despite its revenues beating estimates. As a result, stock price declines.
RHHBYNegative Net Change BMYNegative Net Change HZNPPositive Net Change EPZMPositive Net Change
biotechs
ChemoCentryx (CCXI) Q2 Loss Wider Than Expected, Sales Down
by Zacks Equity Research
ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the second quarter and misses on sales.
VRTXNegative Net Change HZNPPositive Net Change RGENNegative Net Change CCXIPositive Net Change
biotechs earnings medical pharmaceuticals
Biohaven (BHVN) Q2 Earnings Miss, Nurtec Uptake Still Strong
by Zacks Equity Research
Biohaven's (BHVN) sole approved drug, Nurtec ODT for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.
LLYNegative Net Change AMGNNegative Net Change ABBVPositive Net Change BHVNNegative Net Change
biotechs earnings
Why Novavax (NVAX) Stock Fell 19% on Friday
by Madeleine Johnson
Shares of the biotech firm plunged 19.6% in Friday trading after it delayed U.S. submission for its Covid-19 vaccine for the third time.
NVAXNegative Net Change
biotechs coronavirus vaccines